CompaniesDezima Pharma

Dezima Pharma

defunct
About

Defunct Company

Areas of Focus

Categories

Terminally AcquiredBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (4)
View all

Total Trials

4

As Lead Sponsor

0

As Collaborator

4

Total Enrollment

160

By Phase

PHASE1: 3NA: 1

By Status

COMPLETED: 4
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
Today
NCT01889511
Hover over trial bars to see details

Recent Trials

NCT05767632Collaborator
Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)
PHASE1Completed
30 participants
Started: May 30, 2022 · Completed: Oct 25, 2022
NCT05135793Collaborator
Bioequivalence Study of Vonoprazan From Topoprazan 20 mg Tablets (Hikma Pharma, Egypt) Versus Takecab 20 mg Tablets (Takeda Pharmaceutical Co. Ltd., Japan)
PHASE1Completed
29 participants
Started: Jan 19, 2021 · Completed: Mar 1, 2021
NCT05132023Collaborator
Bioequivalence Study of Empagliflozin & Metformin HCL From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)
PHASE1Completed
26 participants
Started: Mar 26, 2019 · Completed: May 15, 2019
NCT01889511Collaborator
Text Messaging to Improve Adherence to Oral Chemotherapy Agents
NACompleted
75 participants
Started: Jun 30, 2013 · Completed: Jun 30, 2015
Related Companies
Amgen Sep 2015
acquired